RCT | The addition of Quizartinib to chemotherapy improves overall survival vs placebo in FLT3-ITD-positive AML patients

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter (thread – click for more)

Acute myeloid leukaemia (AML) is a genetically heterogeneous disease with poor clinical outcomes.

A new study assessed the effect of quizartinib on overall survival in patients with FLT3-ITD-positive newly diagnosed AML, in addition to chemotherapy. https://t.co/MGOoVF5QOa

— The Lancet (@TheLancet) April 27, 2023